Engineering CAR T cells to secrete VEGF-neutralizing scFvs enhances antitumor activity against solid tumors
Authors:
- Torahito A. GaoTGTorahito A. Gao
- Ryan M. ShihRSRyan M. Shih
- Justin D. ClubbJCJustin D. Clubb
- Shao-Hsi HungSHShao-Hsi Hung
- Laura B. James-AllanLJLaura B. James-Allan
- Gabriella DiBernardoGDGabriella DiBernardo
- Amber BourenABAmber Bouren
- Melanie Ayala CejaMCMelanie Ayala Ceja
- Sophie OngSOSophie Ong
- Andréa B. BallABAndréa B. Ball
- 4 March 2026
- journal article
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (839) , eadw9286
Abstract
Chimeric antigen receptor (CAR) T cell therapy has shown limited efficacy against solid tumors, which often reside in highly immunosuppressive tumor microenvironments (TMEs). TMEs can be highly abundant in vascular endothelial growth factor A (VEGF), which contributes to immunosuppression and abnormal tumor vasculature. Here, we found that CAR T cells engineered to secrete an anti-VEGF single-chain variable fragment (CAR-αVEGF T cells) achieved superior antitumor efficacy against multiple in vivo models of ovarian cancer and glioma, outperforming conventional CAR T cells with and without combination anti-VEGF antibody therapy. Microscopy, flow cytometry, and transcriptomic analyses revealed that armoring the CAR T cells with anti-VEGF single-chain variable fragments enhanced their activation and mitochondrial fitness and enriched immune-stimulatory signatures among endogenous immune cells in the tumor-bearing brain. Moreover, CAR-αVEGF T cells circumvented multiple detrimental effects associated with on-target CAR T cell therapy, including infiltration of suppressive myeloid cells, exaggerated vasculature abnormalities, and hypoxia. Together, our results provide rationale for the clinical translation of CAR-αVEGF T cells as a safe and potent therapy for solid tumors characterized by elevated VEGF.Keywords
Funding Information
- National Science Foundation (DGE-2034835)
- National Institutes of Health (2T32CA009120-46A1, 5T32CA009120-45, 5T32CA009120-44)
- National Institutes of Health (NIGMS T32 GM008042; NIGMS T32 GM152342)
- Cancer Research Institute (Lloyd J. Old STAR Award)
- University of California Los Angeles (Whitcome Fellowship)
- Jean and Stephen Kaplan (N/A)
- Department of Veteran Affairs (I01BX006019)
- Department of Veteran Affairs (I01BX006411)
This publication has 74 references indexed in Scilit:
- CAR T Cells and T-Cell Therapies for CancerJAMA, 2024
- STING activation counters glioblastoma by vascular alteration and immune surveillanceCancer Letters, 2023
- Quantifying Intermediary Metabolism and Lipogenesis in Cultured Mammalian Cells Using Stable Isotope Tracing and Mass Spectrometry2019
- Survivin is critically involved in VEGFR2 signaling-mediated esophageal cancer cell survivalBiomedicine & Pharmacotherapy, 2018
- Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating HypoxiaCancer Cell, 2014
- Analysis and Interpretation of Microplate-Based Oxygen Consumption and pH Data2014
- Single chain anti-c-Met antibody conjugated nanoparticles for in vivo tumor-targeted imaging and drug deliveryBiomaterials, 2011
- VEGF directly suppresses activation of T cells from ovarian cancer patients and healthy individuals via VEGF receptor Type 2International Journal of Cancer, 2011
- The vascular endothelial growth factor receptor (VEGFR‐1) supports growth and survival of human breast carcinomaInternational Journal of Cancer, 2006
- Levels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesisInternational Journal of Cancer, 1999